Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | HPGD | P15428 | 3/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.67 |
| ▸ | GAA | P10253 | 3/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.46 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL503252 | 0.81 | MAPT (1.00) | MAPTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL29444102 | 0.81 | MAPT (1.00) | MAPTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL1128076 | 0.81 | MAPT (0.62) | MAPTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL29948882 | 0.81 | MAPT (0.62) | MAPTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL8002675 | 0.72 | MAPT (0.70) | MAPTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL7237225 | 0.71 | GLP1R (0.48) | MAPTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL30939014 | 0.70 | ALDH1A1 (0.67) | MAPTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL3216083 | 0.70 | MAPT (0.48) | MAPTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL31193292 | 0.70 | TDP1 (0.54) | MAPTKDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL3085978 | 0.70 | TDP1 (0.67) | MAPTKDM4EALDH1A1HPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-28 | — | — | US | disclosed |
| EP-2282999-B1 | AMINO-QUINOXALINE AND AMINO-QUINOLINE COMPOUNDS FOR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-05-21 | — | — | EP | disclosed |
| EP-2282999-B1 | AMINO-QUINOXALINE AND AMINO-QUINOLINE COMPOUNDS FOR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-05-21 | — | — | EP | disclosed |
| US-8415353-B2 | Amino-quinoxaline and amino-quinoline compounds for use as adenosine A2a receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415353-B2 | Amino-quinoxaline and amino-quinoline compounds for use as adenosine A2a receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415353-B2 | Amino-quinoxaline and amino-quinoline compounds for use as adenosine A2a receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20110105513-A1 | AMINO-QUINOXALINE AND AMINO-QUINOLINE COMPOUNDS FOR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2011-05-05 | — | — | US | disclosed |
| US-20110105513-A1 | AMINO-QUINOXALINE AND AMINO-QUINOLINE COMPOUNDS FOR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2011-05-05 | — | — | US | disclosed |
| US-20110105513-A1 | AMINO-QUINOXALINE AND AMINO-QUINOLINE COMPOUNDS FOR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2011-05-05 | — | — | US | disclosed |
| EP-2282999-A1 | AMINO-QUINOXALINE AND AMINO-QUINOLINE COMPOUNDS FOR USE AS ADENOSINE A2A RECEPTOR ANTAGONISTS | Schering Corporation (US) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009111442-A1 | AMINO-QUINOXALINE AND AMINO-QUINOLINE COMPOUNDS FOR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2009-09-11 | — | — | WO | disclosed |
| WO-2009111442-A1 | AMINO-QUINOXALINE AND AMINO-QUINOLINE COMPOUNDS FOR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | SCHERING CORPORATION (US) | 2009-09-11 | — | — | WO | disclosed |
| US-6548499-B1 | N-(1-Azabicyclo(2.2.2)octanyl-3-pyridinyl)-3-(2-pyridinyl)-2 -quinoxalinamine, for example; treating various chemokine mediated diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2003-04-15 | — | — | US | disclosed |
| WO-1999042463-A1 | SUBSTITUTED QUINOXALINE DERIVATIVES AS INTERLEUKIN-8 RECEPTOR ANTAGONISTS | WARNER-LAMBERT COMPANY (US) | 1999-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105513-A1 | AMINO-QUINOXALINE AND AMINO-QUINOLINE COMPOUNDS FOR USE AS ADENOSINE A2a RECEPTOR ANTAGONISTS | ADORA2A, ADORA1, ADORA3 | MAPT 3548/4885KDM4E 3727/4885ALDH1A1 855/4885 |
| US-20230301984-A1 | CYCLIC COMPOUNDS FOR USE IN TREATING RETINAL DEGENERATION | ALDH1A2, PDE6D, PDE6C | MAPT 21/4885KDM4E 3316/4885ALDH1A1 145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.